Marc Torrent

Dr. Marc Torrent

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2018 in Science Signaling
Verified
Journal Article
Open access
PDF file
MTMarc Torrent
Marc Torrent
GCGuilhem Chalancon
Guilhem Chalancon
Natalia Sanchez de GrootNatalia Sanchez de Groot
Natalia Sanchez de Groot
AWArthur Wuster
Arthur Wuster
MBM. Madan Babu
M. Madan Babu
Decoding the information in mRNA during protein synthesis relies on tRNA adaptors, the abundance of which can affect the decoding rate and translation efficiency. To determine whether cells alter tRNA abundance to selectively regulate protein expression, we quantified changes in the abundance of individual tRNAs at different time points in response to diverse stress conditions in Saccharomyces cerevisiae. We found that the tRNA pool was dynamic and rearranged in a manner that facilitated selective translation of stress-related transcripts. Through genomic analysis of multiple data sets, stochastic simulations, and experiments with designed sequences of proteins with identical amino acids but altered codon usage, we showed that changes in tRNA abundance affected protein expression independently of factors such as mRNA abundance. We suggest that cells alter their tRNA abundance to selectively affect the translation rates of specific transcripts to increase the amounts of required proteins under diverse stress conditions.

9 February 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MTMarc Torrent
Marc Torrent
DADavid Andreu
David Andreu
VNVictòria M. Nogués
Victòria M. Nogués
Ester BoixEster Boix
Ester Boix
The increasing rate in antibiotic-resistant bacterial strains has become an imperative health issue. Thus, pharmaceutical industries have focussed their efforts to find new potent, non-toxic compounds to treat bacterial infections. Antimicrobial peptides (AMPs) are promising candidates in the fight against antibiotic-resistant pathogens due to their low toxicity, broad range of activity and unspecific mechanism of action. In this context, bioinformatics' strategies can inspire the design of new peptide leads with enhanced activity. Here, we describe an artificial neural network approach, based on the AMP's physicochemical characteristics, that is able not only to identify active peptides but also to assess its antimicrobial potency. The physicochemical properties considered are directly derived from the peptide sequence and comprise a complete set of parameters that accurately describe AMPs. Most interesting, the results obtained dovetail with a model for the AMP's mechanism of action that takes into account new concepts such as peptide aggregation. Moreover, this classification system displays high accuracy and is well correlated with the experimentally reported data. All together, these results suggest that the physicochemical properties of AMPs determine its action. In addition, we conclude that sequence derived parameters are enough to characterize antimicrobial peptides.

3 November 2011 in Bioinformatics
Verified
Journal Article
Open access
PDF file
MTMarc Torrent
Marc Torrent
PTPaolo Di Tommaso
Paolo Di Tommaso
DPDavid Pulido-Gomez
David Pulido-Gomez
MNM. Victòria Nogués
M. Victòria Nogués
CNCedric Notredame
Cedric Notredame
David AndreuDavid Andreu
David Andreu
Summary: AMPA is a web application for assessing the antimicrobial domains of proteins, with a focus on the design on new antimicrobial drugs. The application provides fast discovery of antimicrobial patterns in proteins that can be used to develop new peptide-based drugs against pathogens. Results are shown in a user-friendly graphical interface and can be downloaded as raw data for later examination. Availability: AMPA is freely available on the web at http://tcoffee.crg.cat/apps/ampa. The source code is also available in the web. Contact:marc.torrent@upf.edu; david.andreu@upf.edu Supplementary information: Supplementary data are available at Bioinformatics online.

1 November 2012 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
MTMarc Torrent
Marc Torrent
DPDavid Pulido-Gomez
David Pulido-Gomez
MNM. Victòria Nogués
M. Victòria Nogués
Ester BoixEster Boix
Ester Boix
Antimicrobial proteins and peptides (AMPs) are important effectors of the innate immune system that play a vital role in the prevention of infections. Recent advances have highlighted the similarity between AMPs and amyloid proteins. Using the Eosinophil Cationic Protein as a model, we have rationalized the structure-activity relationships between amyloid aggregation and antimicrobial activity. Our results show how protein aggregation can induce bacteria agglutination and cell death. Using confocal and total internal reflection fluorescence microscopy we have tracked the formation in situ of protein amyloid-like aggregates at the bacteria surface and on membrane models. In both cases, fibrillar aggregates able to bind to amyloid diagnostic dyes were detected. Additionally, a single point mutation (Ile13 to Ala) can suppress the protein amyloid behavior, abolishing the agglutinating activity and impairing the antimicrobial action. The mutant is also defective in triggering both leakage and lipid vesicle aggregation. We conclude that ECP aggregation at the bacterial surface is essential for its cytotoxicity. Hence, we propose here a new prospective biological function for amyloid-like aggregates with potential biological relevance. Microbial infections are reported among the worst human diseases and cause millions of deaths per year over the world. Antibiotics are used to treat infections and have saved more lives than any other drug in human history. However, due to extended use, many strains are becoming refractive to common antibiotics. In this light, new promising compounds, like antimicrobial proteins and peptides (AMPs) are being investigated. Some AMPs also show agglutinating activity; this is the ability to clump bacteria after treatment. This feature is particularly appealing because agglutinating peptides could be used to keep bacteria to the infection focus, helping microbe clearance by host immune cells. In this study, we propose a novel mechanism to explain agglutinating activity at a molecular level using Eosinophil Cationic Protein. We show that the agglutinating mechanism is driven by the protein amyloid-like aggregation at the bacteria cell surface. Accordingly, elimination of the amyloid behavior abolishes both the agglutinating and the antimicrobial activities. This study provides a new concept on how Nature could exploit amyloid-like aggregates to fight bacterial infections. Moreover, these results could also add new insights in understanding the relation between infection and inflammation with dementia and amyloid-related diseases like Alzheimer.

1 July 2012 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
MTMarc Torrent
Marc Torrent
DPDavid Pulido-Gomez
David Pulido-Gomez
LRLuis Rivas
Luis Rivas
DADavid Andreu
David Andreu
Diseases caused by protozoan parasites can pose a severe thread to human health and are behind some serious neglected tropical diseases like malaria and leishmaniasis. Though several different drugs have been developed in order to eradicate these diseases, a successful candidate has not yet been discovered. Among the most active compounds tested, antimicrobial peptides (AMPs) are particularly appealing because of their wide spectrum of action. AMPs have been described to perturb protozoan homeostasis by disrupting the cellular membranes but also by interfering with key processes in the parasite metabolism. In this review we describe the diverse mechanisms of action of AMPs on protozoan targets and how they can be exploited to treat diseases. Moreover, we describe with detail the antimicrobial action of AMPs on two major parasitical infections: leishmaniasis and malaria. All the features reviewed here show that AMPs are promising drugs to target protozoan parasites and that further understanding of the mechanism of action of these compounds will lead to improved drugs that could be worth to test in a clinical phase.

23 February 2008 in Biochemistry
Verified
Journal Article
Closed access
MTMarc Torrent
Marc Torrent
SCSusanna Cantero
Susanna Cantero
MMMohammed Moussaoui
Mohammed Moussaoui
MNM. Victòria Nogués
M. Victòria Nogués
Ester BoixEster Boix
Ester Boix